| Bioactivity | Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II[1][2]. |
| Invitro | Rebeccamycin is an antitumor antibiotic produced by the actinomycete Saccharotrix aerocolonigenes with activity against several human tumor cell lines, including A549 (lung adenocarcinoma), HCT-116 (colon carcinoma), and KB (nasopharyngeal carcinoma) [1].Rebeccamycin shows antibacterial activity against several Gram-positive bacteria, including Staphylococcus aureus and Streptococcus faecalis[3]. |
| Name | Rebeccamycin |
| CAS | 93908-02-2 |
| Formula | C27H21Cl2N3O7 |
| Molar Mass | 570.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Rebeccamycin
CAS: 93908-02-2 F: C27H21Cl2N3O7 W: 570.38
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineopl
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.